PRESS RELEASE

Certara acquires BaseCase

Certara, a developer of model-informed drug development and regulatory science, has announced that it has acquired BaseCase Management GmbH, a data visualisation software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York.

BaseCase, which will join Certara’s Strategic Consulting Services division, has extensive Health Economics and Outcomes Research (HEOR) expertise and is actively working in the area of market access. As a key element in Certara’s data science portfolio, BaseCase technology will soon be leveraged across the company’s industry-leading pharmacometrics, mechanistic modeling, and regulatory science platforms.

The healthcare industry is under increasing pressure to demonstrate the value delivered by new medications and devices. BaseCase’s interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians and healthcare providers, or payers and health authorities.

This cloud-based solution is ideal for companies seeking to build their own bespoke, branded apps to deliver impactful communication of complex models, analyses, and data. By integrating content creation with sales enablement, it allows users to quickly create and personalise a visual value proposition around a drug or device’s ROI and business case.

‘We are delighted that BaseCase is joining Certara and we are looking forward to expanding the applications for its user-friendly, mobile communications technology. BaseCase simplifies communication of complex data and models,’ said Dr Thomas Kerbusch, president of Certara Strategic Consulting Services.

‘BaseCase’s interactive platform will enable pharmaceutical and medical technology companies to visualize model results and large, real-world datasets to make sound decisions quickly, within controlled communication cascades,’ added Dr Kerbusch.

‘The BaseCase team is excited to join Certara and take adoption of our visualization and communications platform to the next level. We are confident that we are a great match. Both companies have comparable cultures – entrepreneurial, dynamic, diverse, and quality driven – and possess a similar mix of scientific and software engineering staff. With the growing acceptance of modeling and simulation in life sciences, comes the need to simplify complex data science concepts and results. Certara is the perfect home for BaseCase,’ said BaseCase CEO Dr Gijs Hubben. 

Financial details about the transaction were not disclosed.

Company: 
Feature

Robert Roe explores efforts to diversify the HPC processor market